Please provide your email address to receive an email when new articles are posted on . Tacrolimus alone had a dose-response relationship with achieving complete renal response in SLE. Combination ...

Early use of mycophenolate mofetil in at-risk patients with SLE reduced the risk of severe flare, potentially delaying lupus nephritis. Early application of mycophenolate mofetil may reduce the ...

MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

Patients with quiescent systemic lupus erythematosus (SLE) who are on maintenance therapy with mycophenolate mofetil (MMF) may be able to be safely weaned off the drug with the understanding that ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Despite new therapies and evolving research, lupus nephritis continues to present clinical and ...

When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and glucocorticoids.

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The ...

Doctors are reporting the first advance in three decades in treating kidney complications from lupus, a life-threatening disease that primarily affects young women. A small study showed that an immune ...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 ...

Margrit Wiesendanger, MD, PhD, discusses how lupus treatment is evolving from traditional therapies to more targeted options like biologics, with promising advances now being explored in clinical ...